10-Q: NextCure Faces Going Concern Doubt Amid Q3 Losses

NextCure, Inc. reported a net loss of $8.6 million for Q3 2025 and disclosed substantial doubt about its ability to continue as a going concern, necessitating immediate capital raises.

Summary

• Net loss for the three months ended September 30, 2025, was $8.6 million, an improvement from $11.5 million in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, increased to $46.4 million from $44.1 million in the prior year, primarily due to a $17 million license fee.
• Cash, cash equivalents, and marketable securities totaled $29.1 million as of September 30, 2025, which is deemed insufficient to fund operations for one year.
• The company has concluded there is substantial doubt about its ability to continue as a going concern.
• A 1-for-12 reverse stock split was effectuated on July 14, 2025.
• The company dosed the first patient in its Phase 1 clinical trial for SIM0505 in October 2025 and expects proof of concept data in the first half of 2026.
• The first patient in the Phase 1 trial for LNCB74 was dosed in January 2025, with proof of concept data also expected in the first half of 2026.
• The company terminated its at-the-market sales agreement with Leerink Partners LLC effective October 8, 2025.

Sentiment

Score: 2

Explanation: The explicit "going concern" warning and the immediate need for substantial additional funding, coupled with a significant accumulated deficit and increased cash burn, indicate a highly negative financial position. While there are some positive clinical updates, the severe liquidity risk overshadows them.

Positives

• Net loss for the three months ended September 30, 2025, decreased to $8.6 million from $11.5 million in the prior year period.
• Net loss per common share for the three months ended September 30, 2025, improved to $(3.22) from $(4.95) in the prior year period.
• Net loss per common share for the nine months ended September 30, 2025, slightly improved to $(18.84) from $(18.91) in the prior year period.
• Research and development expenses for the three months ended September 30, 2025, decreased by $2.6 million compared to the prior year, primarily due to deprioritized programs.
• General and administrative expenses decreased by $0.9 million for the three months and $2.4 million for the nine months ended September 30, 2025, compared to the prior year periods, mainly due to lower personnel-related costs.
• Dosed the first patient in the Phase 1 clinical trial for SIM0505 in October 2025.
• FDA cleared a protocol amendment in November 2025 for LNCB74, allowing higher dose escalation cohorts.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern for a period of one year after the issuance of the financial statements.
• Cash, cash equivalents, and marketable securities of $29.1 million as of September 30, 2025, are insufficient to fund operations for one year.
• Net loss for the nine months ended September 30, 2025, increased to $46.4 million from $44.1 million in the prior year.
• Net cash used in operating activities increased to $42.0 million for the nine months ended September 30, 2025, from $33.8 million in the prior year.
• Accumulated deficit reached $426.5 million as of September 30, 2025.
• Other income, net, decreased by $0.6 million for the three months and $1.8 million for the nine months ended September 30, 2025, due to lower investable cash.
• The at-the-market sales agreement, a potential source of capital, was terminated.

Risks

• Substantial doubt about the ability to continue as a going concern, which may affect future financing and could require curtailment or cessation of operations.
• Need for substantial additional funding in the immediate term to continue planned operations.
• Inability to obtain additional financing on acceptable terms or at all, potentially forcing delays, limits, reductions, or termination of product development or commercialization efforts.
• Potential for investors to lose all or part of their investment if the company is unable to continue as a going concern and liquidates assets.
• Risks related to clinical development, marketing approval, and commercialization of product candidates.
• Unproven approach to the discovery and development of product candidates based on the company's technologies.
• Dependence on key personnel.
• Reliance on and performance of third parties, including collaborators, contract research organizations, and third-party manufacturers.
• Changes in trade tariffs and international relations between the U.S. and China.
• Ability to protect and enforce intellectual property.
• Ability to maintain listing of common stock on the Nasdaq Global Select Market.
• Competition from other therapies and industry developments.
• Potential for dilution if additional funds are raised by issuing equity securities.
• Future debt financing may impose restrictive covenants.
• Requirement to relinquish valuable rights to future revenue streams, product candidates, or research programs if funds are raised through grants, collaborations, or licensing arrangements.

Future Outlook

The company expects to incur substantial expenditures and operating losses for the foreseeable future as it advances SIM0505 and LNCB74 through clinical development, regulatory approval, and potential commercialization. It will require substantial additional funding to support continuing operations and development strategy, with current cash insufficient to fund operations for one year. If adequate funding is not secured, the company may be forced to delay, limit, reduce, or terminate preclinical studies, clinical trials, or development programs, or implement further cost-cutting measures, including potential workforce reductions or pausing clinical programs.

Management Comments

• "We believe that our existing cash, cash equivalents and marketable securities will not be sufficient to fund our planned operations for a period of one year after the issuance of the accompanying unaudited financial statements."
• "Thus, we have concluded that there is substantial doubt about our ability to continue as a going concern."
• "We expect to incur substantial expenditures in the foreseeable future as we advance SIM0505 and LNCB74 through clinical development, the regulatory approval process and, if approved, commercialization."
• "We will need substantial additional funding to support our continuing operations and to pursue our development strategy."
• "If the Company does not raise sufficient funds in one or more financings by year-end or obtain other financial support for program development, the Company will need to implement additional cost cutting measures to extend its runway, which may include delaying enrollment in, or pausing, one of its clinical programs and a further reduction in workforce."

Industry Context

NextCure operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical sector, specifically focusing on oncology with antibody-drug conjugates (ADCs). The company's strategy to license promising candidates like SIM0505 and collaborate on others like LNCB74 is common in the industry for companies seeking to expand their pipeline without solely relying on internal discovery. However, the significant cash burn and going concern warning highlight the inherent financial challenges and high failure rates associated with drug development, particularly for companies without approved products or substantial revenue streams. The focus on CDH6 and B7-H4 targets indicates an attempt to address unmet needs in solid tumors, a crowded but high-value therapeutic area.

Comparison to Industry Standards

• NA The filing does not provide specific comparable company or project data to assess results against global benchmarks. The company is a clinical-stage biopharmaceutical company, and direct comparisons of financial performance are difficult without specific industry peer data or clinical trial success rates for similar ADCs.

Corporate Governance

Legal Proceedings

• Not currently a party to any litigation or legal proceeding that is likely to materially affect the company's business or financial results.
• Evaluates potential loss amounts or ranges for contingencies at each reporting date.

Related Party Transactions

• License Agreement with Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (Zaiming) for SIM0505, involving upfront payments, milestone payments, and royalties.
• Subscription Agreement with Simcere Zaiming, Inc. (an affiliate of Zaiming) for the issuance and sale of 338,636 shares of common stock for $2.0 million.
• Research Collaboration and Co-Development Agreement with LigaChem Biosciences, Inc., involving 50-50 cost and profit sharing for up to three antibody drug conjugates, with LNCB74 being the initial co-development product.

Stakeholder Impact

• Shareholders face significant risk of dilution from future equity raises and potential loss of investment if the company cannot resolve its going concern issues. The reverse stock split may have temporarily boosted share price but does not address underlying financial health.
• Employees experienced a past workforce reduction (37% in March 2024); there is potential for further reductions if additional funding is not secured.
• Creditors may face increased risk due to the company's going concern warning and need for additional capital.
• Partners (Zaiming, LigaChem) have their collaboration success tied to NextCure's financial viability and ability to fund its share of development costs and milestone payments.

Next Steps

• Raise additional capital through partnering, equity sales, or other means.
• Fund the completion of key milestones for clinical programs (SIM0505, LNCB74).
• Fund operations, including research and development activities and employee salaries.
• Provide proof of concept data readout for SIM0505 in the first half of 2026.
• Provide proof of concept data readout for LNCB74 in the first half of 2026.
• Seek partners for NC410 and NC525 programs.
• Pursue a partner or third-party financing for preclinical non-oncology programs NC605 and NC181.
• Implement additional cost-cutting measures if sufficient funds are not raised by year-end, potentially delaying enrollment in or pausing clinical programs and further workforce reductions.
• Pay $5 million to Zaiming by December 31, 2025, or upon a qualifying financing event.
• Pay $1.5 million to Zaiming for the Phase 1 development milestone achieved in October 2025.

Key Dates

Recommendation

The explicit 'substantial doubt about our ability to continue as a going concern' is a critical red flag. With only $29.1 million in cash and equivalents, and a high burn rate ($42.0 million used in operations year-to-date), the company faces an immediate and severe liquidity crisis. While clinical programs show progress, the financial instability and urgent need for capital, coupled with the termination of a previous at-the-market facility, make the investment highly speculative and risky. The potential for significant dilution from future capital raises or the cessation of operations presents a substantial downside for current shareholders.

Keywords

Biopharmaceutical, Oncology, Cancer Treatment, Antibody-Drug Conjugates, ADC, SIM0505, LNCB74, Clinical Stage, SEC Filing, Going Concern, Capital Raise, NXTC, Biotech